Nivolumab
Treatment for Malignant Skin Melanoma
Typical Dosage: 240mg IV every 2 weeks or 480mg IV every 4 weeks
Effectiveness
87%
Safety Score
35%
Clinical Trials
48
Participants
11K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
240mg IV every 2 weeks or 480mg IV every 4 weeks
Time to Effect
3-6 months
Treatment Duration
1-2 years
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$175,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$200,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$185,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$500,000
Cost per Remission
$1,333,333
Comparison vs Ipilimumab
Cost Difference
+$70,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Nivolumab Outcomes
for Malignant Skin Melanoma
Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+40%
Remission Rate
+15%
Common Side Effects
Fatigue
+40%
Rash
+30%
Diarrhea
+20%
Nausea
+20%
Pruritus
+20%
Immune-related adverse events
+15%
Sources:
Active Clinical Trials
7 active trials recruiting for Nivolumab in Malignant Skin Melanoma
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
NCT04309409ACTIVE NOT RECRUITINGPHASE3
374 participants
INTERVENTIONAL
Würzburg, Germany +19 more
Started: Jul 1, 2020
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
NCT06794775RECRUITINGPHASE3
128 participants
INTERVENTIONAL
Gothenburg, Sweden +2 more
Started: Jul 10, 2025
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT04949113ACTIVE NOT RECRUITINGPHASE3
423 participants
INTERVENTIONAL
Los Angeles, United States +23 more
Started: Jul 8, 2021
Melanoma Metastasized to the Brain and Steroids
NCT03563729RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Herlev, Denmark +2 more
Started: Jun 6, 2018
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
NCT07459543NOT YET RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Nashik, India +10 more
Started: Nov 15, 2026
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
NCT05089370ACTIVE NOT RECRUITINGPHASE1, PHASE2
8 participants
INTERVENTIONAL
Aurora, United States
Started: Jun 20, 2022
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
NCT07428252ACTIVE NOT RECRUITINGNA
150 participants
INTERVENTIONAL
Ljubljana, Slovenia
Started: Mar 1, 2022
Completed Clinical Trials
7 completed trials for Nivolumab in Malignant Skin Melanoma
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
NCT07436390COMPLETEDNA
132 participants
INTERVENTIONAL
Ljubljana, Slovenia
Started: Mar 31, 2024
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
NCT02523313COMPLETEDPHASE2
167 participants
INTERVENTIONAL
Berlin, Germany +19 more
Started: Sep 2, 2015
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT01024231COMPLETEDPHASE1
127 participants
INTERVENTIONAL
New Haven, United States +3 more
Started: Dec 14, 2009
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT04382664COMPLETEDPHASE2
156 participants
INTERVENTIONAL
Phoenix, United States +36 more
Started: May 27, 2020
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
NCT02935790COMPLETEDPHASE1
1 participants
INTERVENTIONAL
New York, United States
Started: Sep 30, 2016
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
NCT00441337COMPLETEDPHASE1
39 participants
INTERVENTIONAL
Baltimore, United States +3 more
Started: Aug 1, 2006
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
NCT04133948COMPLETEDPHASE1, PHASE2
44 participants
INTERVENTIONAL
Sydney, Australia +1 more
Started: Jan 7, 2020
Showing 20 of 53 total trials